Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00561756 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00561756: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00561756 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00561756, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from mouse DNA may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of mouse DNA vaccine in treating patients with recurrent B-cell lymphoma.
Interventions
- OTHER flow cytometry
- OTHER immunoenzyme technique
- BIOLOGICAL plasmid DNA vaccine therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-10 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00561756
The ClinicalTrials.gov registry entry for NCT00561756 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which flow cytometry is the first listed.
NCT00561756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00561756 about?
NCT00561756 is a clinical study titled "Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma". RATIONALE: Vaccines made from mouse DNA may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of mouse DNA vaccine in treating patients with recurrent B-cell lymphoma.
What is the current status of trial NCT00561756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2007-10. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00561756?
The interventions under investigation include: flow cytometry (OTHER), immunoenzyme technique (OTHER), plasmid DNA vaccine therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00561756?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.